| Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone R Sackstein, JS Merzaban, DW Cain, NM Dagia, JA Spencer, CP Lin, ... Nature medicine 14 (2), 181-187, 2008 | 755 | 2008 |
| Endosomal escape and delivery of CRISPR/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework SK Alsaiari, S Patil, M Alyami, KO Alamoudi, FA Aleisa, JS Merzaban, M Li, ... Journal of the American Chemical Society 140 (1), 143-146, 2018 | 465 | 2018 |
| Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1 FMV Rossi, SY Corbel, JS Merzaban, DA Carlow, K Gossens, J Duenas, ... Nature immunology 6 (6), 626-634, 2005 | 361 | 2005 |
| NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations AHM Emwas, RM Salek, JL Griffin, J Merzaban Metabolomics 9, 1048-1072, 2013 | 318 | 2013 |
| Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review AH Emwas, C Luchinat, P Turano, L Tenori, R Roy, RM Salek, D Ryan, ... Metabolomics 11, 872-894, 2015 | 259 | 2015 |
| Cell-type-specific CRISPR/Cas9 delivery by biomimetic metal organic frameworks MZ Alyami, SK Alsaiari, Y Li, SS Qutub, FA Aleisa, R Sougrat, ... Journal of the American Chemical Society 142 (4), 1715-1720, 2020 | 193 | 2020 |
| Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs KM Veerman, MJ Williams, K Uchimura, MS Singer, JS Merzaban, S Naus, ... Nature immunology 8 (5), 532-539, 2007 | 159 | 2007 |
| CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution E Drew, JS Merzaban, W Seo, HJ Ziltener, KM McNagny Immunity 22 (1), 43-57, 2005 | 143 | 2005 |
| Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44 DB AbuSamra, FA Aleisa, AS Al-Amoodi, HM Jalal Ahmed, CJ Chin, ... Blood advances 1 (27), 2799-2816, 2017 | 121 | 2017 |
| Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem/progenitor cells JS Merzaban, MM Burdick, SZ Gadhoum, NM Dagia, JT Chu, ... Blood, The Journal of the American Society of Hematology 118 (7), 1774-1783, 2011 | 109 | 2011 |
| Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy SK Alsaiari, SS Qutub, S Sun, W Baslyman, M Aldehaiman, M Alyami, ... Science advances 7 (4), eabe7174, 2021 | 85 | 2021 |
| Efficient fdCas9 synthetic endonuclease with improved specificity for precise genome engineering M Aouida, A Eid, Z Ali, T Cradick, C Lee, H Deshmukh, A Atef, ... PloS one 10 (7), e0133373, 2015 | 69 | 2015 |
| Correlative light‐electron microscopy shows RGD‐targeted ZnO nanoparticles dissolve in the intracellular environment of triple negative breast cancer cells and cause apoptosis … BA Othman, C Greenwood, AF Abuelela, AA Bharath, S Chen, ... Advanced Healthcare Materials 5 (11), 1310-1325, 2016 | 58 | 2016 |
| Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis JS Merzaban, J Imitola, SC Starossom, B Zhu, Y Wang, J Lee, AJ Ali, ... Glycobiology 25 (12), 1392-1409, 2015 | 57 | 2015 |
| Iron-based core–shell nanowires for combinatorial drug delivery and photothermal and magnetic therapy AI Martínez-Banderas, A Aires, M Quintanilla, JA Holguín-Lerma, ... ACS applied materials & interfaces 11 (47), 43976-43988, 2019 | 56 | 2019 |
| Microfluidics-based super-resolution microscopy enables nanoscopic characterization of blood stem cell rolling K AbuZineh, LI Joudeh, B Al Alwan, SM Hamdan, JS Merzaban, ... Science Advances 4 (7), eaat5304, 2018 | 46 | 2018 |
| Magnetic core–shell nanowires as MRI contrast agents for cell tracking AI Martínez-Banderas, A Aires, S Plaza-García, L Colás, JA Moreno, ... Journal of nanobiotechnology 18, 1-12, 2020 | 45 | 2020 |
| CD43 is required for optimal growth inhibition of Mycobacterium tuberculosis in macrophages and in mice AK Randhawa, HJ Ziltener, JS Merzaban, RW Stokes The Journal of Immunology 175 (3), 1805-1812, 2005 | 43 | 2005 |
| Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy SZ Gadhoum, NY Madhoun, AF Abuelela, JS Merzaban Leukemia 30 (12), 2397-2401, 2016 | 38 | 2016 |
| Isolation of cells for selective treatment and analysis using a magnetic microfluidic chip O Yassine, CP Gooneratne, D Abu Smara, F Li, H Mohammed, ... Biomicrofluidics 8 (3), 2014 | 36 | 2014 |
